112 research outputs found

    HIV ๊ฐ์—ผ์ธ์—์„œ ์•„๋ฐ”์นด๋น„์–ด ์•ฝ์ œ๋กœ ์ธํ•œ ๊ณ ํ˜ˆ์•• ๋ฐœ์ƒ์œ„ํ—˜ ํ‰๊ฐ€: ์ฝ”ํ˜ธํŠธ์—ฐ๊ตฌ

    Get PDF
    ํ•™์œ„๋…ผ๋ฌธ (๋ฐ•์‚ฌ)-- ์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› : ์˜๊ณผ๋Œ€ํ•™ ์˜ํ•™๊ณผ, 2019. 2. ๋ฐ•๋ณ‘์ฃผ.Background: While a link between abacavir and CVD risk is suggested, an association between abacavir and hypertension remains unclear. Purpose: To validate the use of claims database in research of HIV-infected individuals, and evaluate the incidence and risk of hypertension induced by abacavir among HIVโ€“infected individuals. Materials and Methods: We constructed a nationwide cohort of HIV-infected individuals using the Health Insurance Review and Assessment Service (HIRA) database of the National Health Insurance System (NHIS) from the period of 2007-2016, and compared the numbers of individuals with the official reports of the government. From 6093 HIV-infected individuals on their initial ART, 1,234 who had used abacavir or non-abacavir ART without switch were were selected after propensity score matching. The use of ART was treated as a time-varying covariate measured as a daily unit. Incidence rate of hypertension was calculated, and Cox proportional hazard models were used to estimate adjusted hazard ratios (HRs) with their 95% confidence interval (CI) of incident hypertension overall and among subgroups. Results: The cohort from HIRA database showed similar numbers of individuals with the ones detected by the government. Among the total 6,093 HIV-infected individuals, incidence rates of hypertension were 4.6 and 3.6 per 100 person-years for abacavir and non-abacavir ART users, respectively. The population attributable fraction of abacavir use on hypertension was 12%. Among the matched 1,234 subjects, abacavir exposure elevated the risk of hypertension among overall study population. However, those aged over 30s, with psychiatric disorders, and diagnosed after the year 2013 were at higher risk of hypertension induced by abacavir. Conclusion: We constructed a database that can be used as a source of HIV epidemiology studies in the future. Those diagnosed after the year 2013 may warrant additional concern for hypertension in patients treated with abacavir.๋ฐฐ๊ฒฝ : ํ•ญ๋ ˆํŠธ๋กœ๋ฐ”์ด๋Ÿฌ์Šค์ œ(ART)์ธ ์•„๋ฐ”์นด๋น„์–ด๋Š” ์‹ฌํ˜ˆ๊ด€๊ณ„์งˆํ™˜์˜ ๋ฐœ์ƒ์œ„ํ—˜๊ณผ ์—ฐ๊ด€์„ฑ์ด ์ œ๊ธฐ๋œ ๋ฐ” ์žˆ์œผ๋‚˜ ๊ณ ํ˜ˆ์••๊ณผ์˜ ์—ฐ๊ด€์„ฑ์€ ์—ฐ๊ตฌ๋œ ์ ์ด ์—†๋‹ค. ๋ชฉ์  : HIV ๊ฐ์—ผ์ธ ์—ฐ๊ตฌ๋ฅผ ๊ฑด๊ฐ•๋ณดํ—˜์ฒญ๊ตฌ์ž๋ฃŒ๋ฅผ ํ™œ์šฉํ•˜์—ฌ ์ˆ˜ํ–‰ํ•˜๋ฉฐ, ๊ฐ์—ผ์ธ์˜ ๊ณ ํ˜ˆ์•• ๋ฐœ์ƒ๋ฅ ๊ณผ ์•„๋ฐ”์นด๋ฐ”์ด์–ด๋กœ ์ธํ•œ ๊ณ ํ˜ˆ์•• ๋ฐœ์ƒ์œ„ํ—˜์„ ํ‰๊ฐ€ํ•œ๋‹ค. ๋ฐฉ๋ฒ• : 2007-2016๋…„ ๊ตญ๋ฏผ๊ฑด๊ฐ•์‹ฌ์‚ฌํ‰๊ฐ€์›์˜ ์ฒญ๊ตฌ์ž๋ฃŒ๋ฅผ ์ด์šฉํ•˜์—ฌ HIV ๊ฐ์—ผ์ž ์ฝ”ํ˜ธํŠธ๋ฅผ ๊ตฌ์ถ•ํ•˜์˜€๋‹ค. ์ „ ๊ตญ๋ฏผ ์ฝ”ํ˜ธํŠธ์—์„œ 6,493๋ช…์˜ ์ฝ”ํ˜ธํŠธ ์ž…์  ๋‹น์‹œ ๊ณ ํ˜ˆ์••์ด ์—†์—ˆ๋˜ ์‹ ๊ทœ ๊ฐ์—ผ๋œ HIV๊ฐ์—ผ์ž๋ฅผ ๋Œ€์ƒ์œผ๋กœ ๊ณ ํ˜ˆ์••์˜ ๋ฐœ์ƒ๋ฅ ์„ ์ถ”์ •ํ•˜๊ณ , ์ด๋ฅผ ํ†ตํ•ด Population attributable fraction(PAF)์„ ์‚ฐ์ถœํ•˜์˜€๋‹ค. ์ด ์—ฐ๊ตฌ๋Œ€์ƒ ์ „์ฒด์™€ ๋…ธ์ถœ๊ตฐ๊ณผ ๋Œ€์กฐ๊ตฐ ๊ฐ„ ์•ฝ๋ฌผ ๋ณ€๊ฒฝ์ด ์—†๋Š” ๊ฐ์—ผ์ธ๋งŒ ๋Œ€์ƒ์œผ๋กœ ์ œํ•œํ•œ ํ›„ propensity score (PS) matching์„ ํ•œ 1,234๋ช…์„ ๋Œ€์ƒ์œผ๋กœ Cox proportional hazard model์„ ์ด์šฉํ•˜์—ฌ abacavir ์•ฝ์ œ๋กœ ์ธํ•œ ๊ณ ํ˜ˆ์•• ๋ฐœ์ƒ์œ„ํ—˜์„ ๊ต๋ž€๋ณ€์ˆ˜๋ฅผ ๋ณด์ •ํ•œ hazard ratio(HR)์™€ 95%์‹ ๋ขฐ๊ตฌ๊ฐ„(CI)์„ ์‚ฐ์ถœํ•˜์˜€๋‹ค. ART ์ฒ˜๋ฐฉ์€ ํ•˜๋ฃจ ๋‹จ์œ„์˜ time-varying covariate๋กœ ์ ์šฉํ•˜์—ฌ ์‹œ๊ฐ„์— ๋”ฐ๋ผ ์ฒ˜๋ฐฉ์—ฌ๋ถ€๊ฐ€ ๋ณ€ํ•˜๋Š” ๊ฒƒ์„ ๋ฐ˜์˜ํ•˜์˜€๋‹ค. ๊ฒฐ๊ณผ: ์ฒญ๊ตฌ์ž๋ฃŒ๋ฅผ ์ด์šฉํ•œ HIV ๊ฐ์—ผ์ธ ์ฝ”ํ˜ธํŠธ๋Š” ์งˆ๋ณ‘๊ด€๋ฆฌ๋ณธ๋ถ€์— ์‹ ๊ณ ๋œ ๊ฐ์—ผ์ธ ์ˆซ์ž์™€ ํฌ๊ฒŒ ๋‹ค๋ฅด์ง€ ์•Š์•˜๋‹ค. ์•„๋ฐ”์นด๋น„์–ด ์ฒ˜๋ฐฉ์ž์™€ ๋น„์ฒ˜๋ฐฉ์ž(๋‹ค๋ฅธ ART ์ฒ˜๋ฐฉ์ž)์˜ ๊ณ ํ˜ˆ์•• ๋ฐœ์ƒ๋ฅ ์€ ๊ฐ๊ฐ 100์ธ๋…„ ๋‹น 4.6๊ณผ 3.6์ด์—ˆ๊ณ , ์ด๋กœ๋ถ€ํ„ฐ PAF์€ 12๋กœ ์‚ฐ์ถœ๋˜์—ˆ๋‹ค. ์•ฝ์ œ๋ณ€๊ฒฝ์—†๋Š”๊ตฐ ๋‚ด์—์„œ PS matching๋œ ๋Œ€์ƒ์—์„œ ์•„๋ฐ”์นด๋น„์–ด ๋…ธ์ถœ์€ ๊ณ ํ˜ˆ์•• ๋ฐœ์ƒ์˜ ์œ„ํ—˜์„ ๋†’์ด๋Š” ๊ฒƒ์œผ๋กœ ๋‚˜ํƒ€๋‚ฌ์œผ๋‚˜ ํ†ต๊ณ„์ ์œผ๋กœ ๊ฒฝ๊ณ„์„ฑ ์œ ์˜์„ฑ์„ ๋ณด์˜€๋‹ค(HR 1.7 [95%CI, 1.0-3.0], P value, 0.06). ์ด ์—ฐ๊ด€์„ฑ์— 30๋Œ€ ์ด์ƒ์˜ ์—ฐ๋ น, ์ •์‹ ๊ณผ ์งˆํ™˜์˜ ๋ณ‘๋ ฅ, 2013๋…„ ์ดํ›„ ์ง„๋‹จ ์ด๋ ฅ์€ ์œ ์˜ํ•˜๊ฒŒ ์˜ํ–ฅ์„ ๋ฏธ์น˜๋Š” ์ธ์ž๋กœ ๋‚˜ํƒ€๋‚ฌ๋‹ค. ๊ฒฐ๋ก  : ๊ฑด๊ฐ•๋ณดํ—˜์ฒญ๊ตฌ์ž๋ฃŒ๋ฅผ ์ด์šฉํ•˜์—ฌ HIV ๊ฐ์—ผ์ธ์— ๋Œ€ํ•œ ์—ญํ•™์—ฐ๊ตฌ๊ฐ€ ๊ฐ€๋Šฅํ•œ ์ž๋ฃŒ์› ๊ตฌ์ถ•์„ ํ†ตํ•ด ํ–ฅํ›„ ์ด ์ž๋ฃŒ์›์˜ ํ™œ์šฉ๊ฐ€์น˜๊ฐ€ ํฌ๋‹ค. ์•„๋ฐ”์นด๋น„์–ด ์•ฝ์ œ ์ฒ˜๋ฐฉ ์‹œ ํ˜ˆ์••์— ๋Œ€ํ•œ ๋ชจ๋‹ˆํ„ฐ๋ง์ด ํ•„์š”ํ•˜๋ฉฐ, ART ์ˆœ์‘๋„๊ฐ€ ๋†’์€ ์ตœ๊ทผ ์ง„๋‹จ์ž์—์„œ ํŠนํžˆ ๊ทธ๋Ÿฌํ•˜๋‹ค.Contents 1. Introduction 1 1.1 Background 1 1.1 Objectives 2 2. Materials and Methods 2 2.1 Data source 2 2.2 Study population 3 2.3 Assessment of exposure and outcome definitions 3 2.4 Potential confounders 4 2.5 Statistical analysis 5 2.6 Sensitivity analysis 6 3. Results 7 3.1 Cohort compared to the KCDC reports 7 3.2 Main results of CPH models 9 3.3 Sensitivity analysis results of outcomes 13 3.4 Sensitivity analysis results of subjects 15 4. Discussion 22 5. Conclusion 26 6. References 27 7. Abstract (Korean) 30Docto

    ๆœ้ฎฎๅพŒๆœŸ ๅฐๆทธ่ฒฟๆ˜“ ์ „๊ฐœ์™€ ่ฒฟๆ˜“ๆ”ถ็จ…ๅˆถ์˜ ์‹œํ–‰

    No full text
    ํ•™์œ„๋…ผ๋ฌธ(์„์‚ฌ)--์„œ์šธๅคงๅญธๆ ก ๅคงๅญธ้™ข :ๅœ‹ๅฒๅญธ็ง‘,1996.Maste

    ๊ธฐ๊ณ„์  ์ž๊ทน์— ์˜ํ•œ ์กฐ์ƒ์•„์„ธํฌ์˜ ATP๋ถ„๋น„

    No full text
    ํ•™์œ„๋…ผ๋ฌธ (์„์‚ฌ)-- ์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› : ์น˜์˜ํ•™๊ณผ, 2012. 2. ๊น€์ค‘์ˆ˜.์น˜ํ†ต์€ ๋…ธ์ถœ๋œ ์ƒ์•„์งˆ์— ๊ฐ€ํ•ด์ง€๋Š” ๋‹ค์–‘ํ•œ ์ž๊ทน์— ์˜ํ•ด ๋‚˜ํƒ€๋‚  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์กฐ์ƒ์•„์„ธํฌ์˜ ์œ„์น˜๋‚˜ ํ˜•ํƒœ์˜ ๋ณ€ํ™”๊ฐ€ ์น˜ํ†ต์„ ์œ ๋ฐœํ•˜๋Š” ์š”์ธ์œผ๋กœ ์•Œ๋ ค์ ธ ์žˆ์œผ๋‚˜ ๊ทธ ๊ธฐ์ „์€ ๋ช…ํ™•ํ•˜๊ฒŒ ๋ฐํ˜€์ง€์ง€ ์•Š๊ณ  ์žˆ๋‹ค. ๊ทธ๋ฆฌ๊ณ  ATP๋Š” ์‹ ๊ฒฝ๋ง๋‹จ์— ๋ถ„ํฌํ•˜๋Š” P2X ์ˆ˜์šฉ์ฒด๋ฅผ ํ™œ์„ฑํ™”์‹œํ‚ด์œผ๋กœ์จ ๋™ํ†ต์œ ๋ฐœ์— ๊ด€์—ฌํ•˜๋Š” ๋ฐ”, ๋ณธ ์—ฐ๊ตฌ์—์„œ๋Š” ์กฐ์ƒ์•„์„ธํฌ์˜ ๋ณ€ํ˜•์— ์˜ํ•ด ATP๊ฐ€ ์œ ๋ฆฌ๋จ์„ ํ™•์ธํ•จ์œผ๋กœ์จ ์น˜ํ†ต๋ฐœ์ƒ์— ๋Œ€ํ•œ ์กฐ์ƒ์•„์„ธํฌ์˜ ์—ญํ• ์„ ๋ฐํžˆ๊ณ ์ž ํ•˜์˜€๋‹ค. ์กฐ์ƒ์•„์„ธํฌ์˜ ํŠน์„ฑ์„ ์ž˜ ๋‚˜ํƒ€๋‚ด๋Š” MDPC-23 ์„ธํฌ์ฃผ๋ฅผ ๋ฐฐ์–‘ํ•˜์—ฌ ์ €์žฅ์„ฑ ์šฉ์•ก์œผ๋กœ ๊ธฐ๊ณ„์  ์ž๊ทน์„ ๊ฐ€ํ•˜์˜€๋‹ค. ์ €์žฅ์„ฑ ์šฉ์•ก์€ 200, 230, 260 mOsm์„ ์‚ฌ์šฉํ•˜์˜€์œผ๋ฉฐ, ๋ฐฐ์–‘ํ•œ ์„ธํฌ์ฃผ๋ฅผ ์ •์ƒ ๋“ฑ์žฅ์„ฑ ์šฉ์•ก๊ณผ ์ €์žฅ์„ฑ ์šฉ์•ก์— 15๋ถ„๊ฐ„ ๋…ธ์ถœ์‹œํ‚ค๊ณ , ๋ฐฐ์–‘์•ก๋‚ด์˜ ATP ๋†๋„๋ฅผ luciferin- luciferase bioluminescence assay ๋ฒ•์œผ๋กœ ์ •๋Ÿ‰ํ•˜์˜€๋‹ค. ATP์œ ๋ฆฌ๊ฐ€ ๊ธฐ๊ณ„์  ์ˆ˜์šฉ์ฒด์— ์˜ํ•ด ์ผ์–ด๋‚˜๋Š”์ง€๋ฅผ ํ™•์ธํ•˜๊ธฐ ์œ„ํ•ด ๊ธฐ๊ณ„์  ์ž๊ทน์— ์˜ํ•ด ํ™œ์„ฑํ™”๋˜๋Š” ๋น„ํŠน์ด์„ฑ ์–‘์ด์˜จ ์ฑ„๋„ ์–ต์ œ์ œ์ธ gadolinium(50ฮผM)์˜ ํšจ๊ณผ๋„ ๊ด€์ฐฐํ•˜์˜€๋‹ค. ์ €์žฅ์„ฑ ์šฉ์•ก์€ ์กฐ์ƒ์•„์„ธํฌ์ฃผ์—์„œ ์ •์ƒ ๋“ฑ์žฅ์„ฑ์šฉ์•ก์— ๋น„ํ•ด ATP์œ ๋ฆฌ๋ฅผ ์ฆ๊ฐ€์‹œ์ผฐ์œผ๋ฉฐ, ๋ฐฐ์–‘์•ก์˜ ์‚ผํˆฌ์งˆ ๋†๋„๊ฐ€ ๋‚ฎ์•„์งˆ์ˆ˜๋ก ATP์œ ๋ฆฌ๊ฐ€ ์ฆ๊ฐ€ํ•˜๋Š” ๊ฒฝํ–ฅ์„ ๋ณด์˜€์œผ๋‚˜ gadolinium์€ ๊ธฐ๊ณ„์  ์ž๊ทน์— ์˜ํ•œ ATP์œ ๋ฆฌ๋ฅผ ์–ต์ œํ•˜์ง€ ๋ชปํ•˜์˜€๋‹ค.Maste

    1770-1810๋…„๋Œ€ ์˜๊ตญ ์—ฌ์„ฑ์†Œ์„ค์˜ ์ „๊ฐœ : Burney, Edgeworth, Austen ์—ฐ๊ตฌ

    No full text
    ํ•™์œ„๋…ผ๋ฌธ(๋ฐ•์‚ฌ)--์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› :์˜์–ด์˜๋ฌธํ•™๊ณผ ๋ฌธํ•™์ „๊ณต,2001.Docto

    ์•„ํŒŒํŠธ ์ฃผ๊ฑฐ๋ฌธํ™”์˜ ์‹คํƒœ์™€ ๋ณ€ํ™” : ํ‰์ดŒ ์‹ ๋„์‹œ ์‚ฌ๋ก€ ์—ฐ๊ตฌ

    No full text
    ํ•™์œ„๋…ผ๋ฌธ(์„์‚ฌ)--์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› :์ธ๋ฅ˜ํ•™๊ณผ ์ธ๋ฅ˜ํ•™์ „๊ณต,2003.Maste

    ์—ฌ์„ฑ์˜ ์ด๋ฆ„๊ณผ ์ •์ฒด์„ฑ์˜ ๋ฌธ์ œ-ํ”„๋žœ์”จ์Šค ๋ฒ„๋‹ˆ์˜ '์”จ์‹ค๋ฆฌ์•„๋ก '

    No full text
    ํ”„๋žœ์”จ์ฆˆ ๋ฒ„๋‹ˆ (Frances Burney, 1752-1840)๋Š” ํ”ํžˆ ํŒจ๋‹ˆ ๋ฒ„๋‹ˆ (Fanny Burney) ํ˜น์€ ๋งˆ๋‹ด ๋‹ค๋ธ”๋ ˆ์ด(Madame d'Arblay)๋ผ๊ณ  ์•Œ๋ ค์ง„ ์˜๊ตญ ์—ฌ์„ฑ์ž‘๊ฐ€์ด๋‹ค. ์ข…๋ž˜์˜ ์˜๊ตญ๋ฌธํ•™์‚ฌ์—์„œ ๋ฒ„๋‹ˆ๋Š” ์ƒˆ๋ฎค์—˜ ์กด์Šจ(Samuel Johnson) ๋ฅ˜์˜ ๋„๋•์ฃผ์˜์  ์ž‘๊ฐ€๋กœ, 18์„ธ๊ธฐ์˜ ์ฃผ์š”ํ•œ ๋‚จ์„ฑ์†Œ์„ค๊ฐ€๋“ค๊ณผ ์ œ์ธ ์˜ค์Šคํ‹ด(Jane Austen)์˜ ์‚ฌ์ด์— ๋ฌปํ˜€ ์•„์˜ˆ ๊ฑฐ๋ก ๋˜์ง€ ์•Š๊ฑฐ๋‚˜ ์•„๋‹ˆ๋ฉด ๊ณผ๋„์  ์ธ๋ฌผ" (a transitional figure) ์ •๋„๋กœ ์–ธ๊ธ‰๋˜๊ณค ํ–ˆ๋‹ค. ๊ทธ๋Ÿฐ๋ฐ 1970๋…„๋Œ€ ์ด๋ž˜๋กœ ์—ฌ์„ฑ๋ก  ๋น„ํ‰์€ ๋ฒ„๋‹ˆ๋ฅผ ์žฌํ‰๊ฐ€ํ•˜๋ฉด์„œ ๋ฒ„๋‹ˆ ๋ฌธํ•™์˜ ์‚ฌํšŒ๋น„ํŒ, 18์„ธ๊ธฐ ์—ฌ์„ฑ ์†Œ์„ค๊ฐ€๋กœ์„œ ๊ฒช์€ ์–ด๋ ค์›€๊ณผ ๊ฐˆ๋“ฑ ๋“ฑ์— ์ฃผ๋ชฉํ•ด ์™”๋‹ค. ๋ฌด์—‡๋ณด๋‹ค๋„ ํฅ๋ฏธ๋กœ์šด ์ ์€ ์ตœ๊ทผ์˜ ๋ฒ„๋‹ˆ ์—ฐ๊ตฌ์ž๋“ค์ด ์šฐ์„  ๋ฒ„๋‹ˆ์˜ ์ด๋ฆ„๋ถ€ํ„ฐ ๋ฐ”๋กœ์žก์•„์•ผ ํ•œ๋‹ค๊ณ  ์ฃผ์žฅํ•œ๋‹ค๋Š” ์‚ฌ์‹ค์ด๋‹ค. ๋‘๋””(Margaret Anne Doody)์— ๋”ฐ๋ฅด๋ฉด ์ •์ž‘ ๋ฒ„๋‹ˆ ์ž์‹ ์€ ํŒจ๋‹ˆ ๋ผ๋Š” ์ด๋ฆ„์œผ๋กœ ์ถœํŒํ•œ ์ ์ด ์—†๋Š”๋ฐ๋„ ์ง€๋‚œ ํ•œ์„ธ๊ธฐ ๋™์•ˆ ์šฐ๋ฆฌ๋Š” ํŒจ๋‹ˆ๋ผ๋Š” ์ด๋ฆ„์„ ์จ์™”์œผ๋ฉฐ, ์ด ์ด๋ฆ„์€ ์–•์žก์•„๋ณด๋Š” ์• ์นญ" (a patronizing diminutive)์œผ๋กœ ๋งŽ์€ ํ‰์ž๋“ค์ด ์›ํ•˜๋Š”๋Œ€๋กœ ์ž‘๊ฐ€๊ฐ€ ์•…์˜ ์—†๊ณ  ์–ด๋ฆฐ์• ๊ฐ™์œผ๋ฉฐ ๊ทธ์ € ์•„๋Š” ์ฒดํ•˜๋Š” ๋ฏธ์„ฑ์ˆ™ํ•œ ์—ฌ์„ฑ์œผ๋กœ ๋ณด์ด๊ฒŒ ํ•˜๋Š”๋ฐ, ์ด๋Š” ๋น„์œ ์ปจ๋Œ€ ๋งˆ์น˜ ใ€Ž๋งจ์Šคํ•„๋“œ ํŒŒํฌใ€(Mansfield Park)์˜ ์—ฌ์ฃผ์ธ๊ณต์ด ์†Œ์„ค๊ฐ€๋กœ ๋‚˜์„  ๊ฒƒ์ฒ˜๋Ÿผ ๋“ค๋ฆฐ๋‹ค." ๋ฒ„๋‹ˆ ์‚ฌํ›„์— ์ถœํŒ๋œ ์ผ๊ธฐ๋“ค์€ ํŒจ๋‹ˆ๋ผ๋Š” ์• ์นญ์„ ์นœ์ˆ™ํ•˜๊ฒŒ ๋งŒ๋“ค๋ฉด์„œ ์žฌ์น˜์žˆ๋Š” ์ˆ˜๋‹ค์žฅ์ด์˜ ๋ช…์„ฑ์„ ๋†’์ด๋Š” ๊ฐ€์šด๋ฐ ์†Œ์„ค๊ฐ€์˜ ๋ชจ์Šต์„ ํ‡ด์ƒ‰์‹œ์ผฐ์œผ๋ฉฐ, ๋ฒ„๋‹ˆ์˜ ์ž‘ํ’ˆ์ด ํ›„๊ธฐ๋กœ ๊ฐˆ์ˆ˜๋ก ๋ฌธํ•™์  ์„ฑ์ทจ๋„๊ฐ€ ๋–จ์–ด์ง„๋‹ค๊ณ  ์ƒ๊ฐํ•˜๋Š” ๊ธฐ์กด์˜ ๋น„ํ‰๊ฐ€๋“ค์€ ์žฌ๊ธฐ๋ฐœ๋ž„ํ•˜๋˜ ํŒจ๋‹ˆ ๋ฒ„๋‹ˆ๊ฐ€ ๋„๋•์ฃผ์˜์ ์ธ ๋งˆ๋‹ด ๋‹ค๋ธ”๋ ˆ์ด๋กœ ์˜๋ฝ ํ–ˆ๋‹ค๊ณ  ์•„์‰ฌ์›Œํ•œ๋‹ค. ๋‘๋””์™€ ์— ์Šคํƒ€์ธ(Julia Epstein)์ด ์ž‘๊ฐ€์˜ ๋ณธ๋ž˜ ์ด๋ฆ„์ธ ํ”„๋žœ์”จ์ฆˆ๋ฅผ ๋˜์ฐพ์•„ ์ฃผ๋ ค๋Š” ๊ฒƒ์€ ๊ธฐ์กด์˜ ๋ฒ„๋‹ˆ ์—ฐ๊ตฌ๊ฐ€ ๋ณด์—ฌ์˜จ ์„ ์ž…๊ด€์„ ๋ฐฐ์ œํ•˜๋Š” ๋น„ํ‰์˜ ์ถœ๋ฐœ์ ์„ ๋งˆ๋ จํ•˜๋Š” ๊ฒƒ์ด๋‹ค

    Modeling and Forecasting Performances for Foreign Investor\๏ฝ€s Return

    No full text
    Maste
    • โ€ฆ
    corecore